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Abstract  Percutaneous  treatments  for  liver  tumors  were  initially  reserved  for  patients
deemed  to  be  inoperable  and  whose  tumors  were  small  in  both  size  and  number.  As  a  result
of the  widening  range  of  both  techniques  and  technologies  these  treatments  have  gradually
become incorporated  into  increasingly  complex  treatment  strategies  for  increasingly  broad
patient groups.  The  place  reserved  for  these  techniques,  which  are  still  dominated  by  monopo-
lar radiofrequency  ablation,  which  is  now  facing  strong  competition  from  second-generation
microwaves,  is  governed  by  each  center’s  knowledge  and  skills  in  the  techniques.  This  review
describes the  possible  indications  for  percutaneous  ablation  depending  on  clinical  ﬁndings  andablation;
Electroporation
the technical  and  technological  choices  made.
© 2014  Éditions  franc¸aises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
In  the  last  two  decades,  percutaneous  treatments  for  malignant  liver  tumors  have  advanced
considerably.  They  are  better  tolerated  than  partial  hepatectomy  [1—3]  and  can  radically
treat  tumors,  which  are  small  in  both  size  and  number  with  very  few  contraindications
[4,5].  The  most  widely  used  method  of  those  available  has  been  monopolar  radiofrequency
ablation,  although  in  the  last  2  years  this  has  attracted  strong  competition  from  microwaves
[6],  which  have  seen  major  technological  advances.  Other  techniques  such  as  multipolar
radiofrequency  ablation  [7]  and  irreversible  electroporation  [8]  use  implantation  of  several
electrodes  operating  in  pairs  in  bipolar  mode.  These  methods,  which  are  conceptually
very  different  from  monopolar  radiofrequency  ablation  and  microwaves,  are  bringing  new
prospects  for  treatment.
Generally,  compared  to  older  chemical  methods  such  as  alcoholization,  physical  abla-
tion  techniques  produce  more  predictable  results,  which  are  almost  independent  of  the
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Figure 1. a: diagrammatic representation of an ablation area
with ideal centrifugal extension from a central tumor energy
source: monopolar, mono-electrode radiofrequency (RF) ablation,
mono-aerial microwave ablation, monoﬁber laser ablation, mono-
applicator cryoablation; b: diagrammatic representation of ablation
by ideal summation (sequential or simultaneous) of three ablation
areas with isometric centrifugal extension from three paracentral
energy sources within the tumor. Multi-electrode, monopolar RF
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trodes,  which  are  activated  sequentially  in  pairs  (Fig.  2).
It  is  no  longer  necessary  with  this  device  therefore  to  use
a  dispersion  electrode  as  all  the  energy  produced  by  the
generator  is  delivered  into  the  treatment  area.  Unlike  the
Figure 2. Diagrammatic representation of multipolar ablation by
sequential bipolar activation of all electrode pairs (three electrodes
allowing three possible combination of electrodes pairs). The abla-
tion area extends centripetally between the three energy sources66  
ype  of  tumor.  Several  randomized  trials  [9—11]  have  con-
rmed  that  radiofrequency  ablation  is  superior  for  the
reatment  of  hepatocellular  carcinoma  (HCC).  There  has
een  an  underlying  trend  in  the  last  few  years  to  use
rst  line  percutaneous  physical  ablation  techniques  to  treat
mall  malignant  liver  tumors  in  favor  of  excision  surgery
3,5,12—14].
uiding and monitoring percutaneous
epatic ablation
ltrasound  computed  tomography  (CT)  and  to  a  lesser
xtent,  magnetic  resonance  imaging  (MR)  can  be  used
or  percutaneous  hepatic  ablation.  The  choice  of  method
epends  less  on  the  operator’s  usual  practice  than  on  the
ntrinsic  properties  of  each  of  the  methods.  There  are  no
omparative  studies  available  as  yet  on  this  subject  and
t  is  quite  remarkable  that  almost  all  of  the  major  series
ublished  have  been  carried  out  under  ultrasound  guiding
nd  monitoring  [4,5,12].  This  preference  in  the  expert  cen-
ers  is  undoubtedly  partially  explained  by  its  low  cost  and
eady  availability  of  ultrasound.  Furthermore,  however,  the
ntrinsic  properties  of  ultrasound:  multiplanar  examination,
eal  time  and  excellent  unenhanced  tissue  contrast  reso-
ution  makes  ultrasound  perform  extremely  well  in  guiding
nd  monitoring  percutaneous  ablation  of  liver  tumors  [15].
he  predominant  role  of  ultrasound  in  this  situation  should
e  further  increased  by  the  use  of  microbubble  contrast
edia  and  the  major  advances  in  3D  imaging,  fusion  and
nstrumentalized  geolocalization  [16].
The  new  ﬂat  sensor  angiography  tables  allow  3D  CT-like
mages  to  be  obtained  and  should  shortly  also  become  nec-
ssary  guiding  and  early  assessment  tools  for  percutaneous
blation  techniques.  In  addition,  and  unlike  CT,  they  offer
aximum  patient  accessibility  making  ultrasound  extremely
asy  to  use  simultaneously  in  guiding  and  monitoring  proce-
ures.
adiofrequency ablation technologies and
heir  results
he  generic  term  ‘‘radiofrequency’’  in  reality  poorly  reﬂects
he  large  technological  differences  between  instruments.
onopolar  mode,  which  is  still  at  present  by  far  the  most
idely  used  (a  generator  connected  to  two  electrodes:  one
ctive  electrode  is  implanted  in  the  center  of  the  treatment
rea  and  the  second  ‘‘passive’’  electrode  is  a  dispersion
late  stuck  onto  the  patient’s  skin)  in  fact  groups  together
everal  devices  which  are  very  different  in  design  (Fig.  1).  In
rder  to  increase  the  volume  of  tissue  destroyed  by  impact
ith  these  systems,  energy  diffusion  from  the  active  elec-
rode  implanted  in  the  tumor  must  be  improved.  Three
ajor  concepts  have  been  developed  to  achieve  this;  these
iffer  mostly  in  the  design  of  the  electrodes,  which  may
ither  be  linear  or  deployable.
A  few  animal  model  studies  have  shown  that  the  shape
nd  volume  of  the  ablation  areas  obtained  in  the  liver  can
ary  depending  on  the  monopolar  device  used  [17,18].  Dif-
erences  can  also  be  seen  on  an  intention-to-treat  basis  as
he  feasibility  of  treatment  varies  for  a  given  site  depending
i
ﬁ
t
rblation, multi-aerial microwave ablation, multiﬁber laser ablation,
ulti-applicator cryoablation.
n  the  design  of  the  electrode.  Deployable  electrodes  are
ore  difﬁcult  to  use  for  superﬁcial  tumors.  Linear  elec-
rodes,  which  are  not  bulky  and  can  be  seen  in  a  single  plane
ection,  are  undoubtedly  more  straightforward  to  position,
articularly  for  sites  considered  to  be  difﬁcult.
Another  system  operating  in  multipolar  mode  has  been
vailable  in  clinical  practice  for  several  years.  This  involves
mplanting  several  (up  to  six)  cooled  bipolar  linear  elec-mplanted in the periphery of the tumor or even, if the tumor is suf-
ciently small, outside of the tumor = ‘‘no touch’’ technique. This
ype of procedure is only possible with multi-electrode multipolar
adiofrequency and irreversible electroporation.
2014
i
a
t
t
t
I
b
r
r
m
u
r
i
t
m
e
m
f
(
1
o
o
a
r
f
p
I
a
I
c
t
(
c
e
t
c
r
d
t
p
e
i
t
i
i
a
r
p
m
b
r
p
aPercutaneous  hepatic  ablation:  What  needs  to  be  known  in  
monopolar  systems,  the  tissue  is  not  destroyed  by  centrifu-
gal  diffusion  of  heat  from  the  electrode  but  centripetally
in  the  spaces  between  each  electrode  pair.  As  a  result,  in
multipolar  mode  it  is  no  longer  the  center  of  the  tumor
but  its  periphery,  which  needs  to  be  punctured.  Compared
to  conventional  monopolar  devices,  this  system  has  several
fundamental  advantages:  improved  energy  efﬁciency  for
the  same  sample  power  and  in  particular  more  predictable
margins  of  the  ablation  areas  produced  (determined  by
implanting  the  electrodes).  These  advantages  have  been
demonstrated  in  several  pilot  studies,  which,  in  particu-
lar,  have  shown  that  it  has  become  possible  to  completely
destroy  tumors  with  a  diameter  well  in  excess  of  three
centimeters  [19,20].  In  addition,  in  multipolar  mode,  it  is
no  longer  necessary  to  puncture  the  tumors  themselves,
which  can  be  treated  using  the  concept  of  ‘‘no  touch  abla-
tion’’,  borrowed  from  oncology  surgery  [19].  As  a  result,  far
more  than  being  a  technological  advance,  multipolar  mode
has  introduced  a  genuine  paradigm  shift  into  percutaneous
tumor  ablation.
Microwave technologies and their results
Like  radiofrequency,  microwave  is  a  hyperthermia  ablation
technique  and  Penn’s  biothermodynamic  equation  [21]  also
applies  when  modeling  the  ﬁnal  result  of  tissue  destruc-
tion  by  microwave  ablation.  In  addition,  like  monopolar
radiofrequency  ablation,  energy  is  propagated  centrifugally
from  the  electrode  (aerial).  Here  again,  several  electrodes
can  be  used  simultaneously,  as  in  monopolar  radiofrequency
ablation,  to  increase  the  ablation  volume  primarily  by  sum-
mating  the  areas  of  destruction  around  each  electrode.  If
the  intention  is  to  create  a  continuous  area  of  ablation,
as  in  monopolar  radiofrequency  ablation  the  aerials  need
to  be  positioned  in  such  a  way  that  the  individual  ablation
areas  overlap  (Fig.  1).  If  the  intention  is  to  obtain  the  same
result  with  a  single  aerial,  as  in  single  electrode  monopolar
radiofrequency  ablation,  several  successive  ablation  cycles
need  to  be  performed,  moving  the  aerial  after  each  impact
in  order  to  overlap  the  areas  destroyed.
By  design,  therefore,  microwave  is  subject  to  the  same
limitations  as  conventional  monopolar  radiofrequency  abla-
tion,  although  the  second-generation  microwave  devices,
which  have  recently  become  available,  have  reignited  inter-
est  in  the  technology,  as  the  transfer  of  microwave  energy
to  tissue  is  more  efﬁcient  than  with  radiofrequency.  A
microwave  electromagnetic  wave  excites  water  molecules
over  a  radius  of  approximately  2  cm  (from  the  center  of
the  aerial)  whereas  a  radiofrequency  wave  mobilizes  ionic
charges  located  within  a  radius  of  just  a  few  millimeters
around  the  electrode.  With  microwave,  therefore,  the  pas-
sive  tissue  heat  conduction  effect  contributes  less  to  the
ﬁnal  volume  of  the  area  destroyed  than  with  radiofrequency
ablation.  The  microwave  temperature  peaks  are  higher  and
achieved  faster  than  with  radiofrequency.  In  addition,  and
unlike  radiofrequency  ablation,  carbonization  of  tissue  in
contact  with  the  microwave  aerial  (which  generally  occurs
as  the  temperatures  reached  are  >  100 ◦C)  does  not  stop  the
process  of  energy  transfer  to  the  tissue.
How  does  this  work  in  clinical  practice?  It  is  clear  that
for  the  equivalent  volume  of  tissue  destruction  microwave
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s  considerably  faster  than  radiofrequency  ablation  [22],
lthough  at  present  there  are  no  convincing  clinical  results
o  conﬁrm  that  it  is  possible  with  microwave  to  extend
he  limits  of  maximum  tumor  size,  which  can  be  destroyed
hrough  impact  without  increasing  the  risk  of  complications.
n  practice,  and  as  with  monopolar  radiofrequency  ablation
eyond  1.5  cm  either  side  of  the  electrode  with,  the  ﬁnal
esults  are  variable  a  single  energy  delivery  cycle  (without
epositioning),  as  they  are  very  dependent  on  the  tissue
acro-  and  microperfusion  conditions.  In  addition,  and
nlike  radiofrequency  ablation  in  which  tissue  impedance
outinely  rises  during  the  procedure,  with  microwave  there
s  currently  no  tissue  feedback,  which  can  be  used  to  judge
he  progress  of  the  ablation.  The  charts  provided  by  the
anufacturers  are  of  limited  use  as  they  are  produced  from
x  vivo  experiments.  The  increase  in  ablation  volumes  by
icrowave  reported  in  some  clinical  studies  is  more  due  to
requent  repositioning  of  the  aerials  during  the  procedures
facilitated  by  the  short  energy  delivery  cycles  of  1/3  to
/2  of  those  with  RF)  than  to  the  greater  intrinsic  efﬁciency
f  microwave  [23].  At  present,  there  is  therefore  no  seri-
us  argument  to  routinely  recommend  the  use  of  microwave
blation  to  treat  tumors  over  3  cm  in  size.  As  with  monopolar
adiofrequency  ablation,  the  need  to  reposition  electrodes
or  tumors  over  3  cm  in  size  makes  microwave  ablation  less
redictable  and  higher  risk.
rreversible electroporation technology
nd  its results
rreversible  electroporation  causes  delayed  or  immediate
ell  death  by  permanently  damaging  the  membrane  func-
ion  of  cells  which  are  exposed  to  a  very  high  potential
1000  V—3000  V)  high  intensity  (20  A—50  A)  pulsed  electri-
al  ﬁeld  lasting  a  few  microseconds  (50  s—90  s)  [8].  These
lectromagnetic  ﬁeld  pulses  trigger  massive  local  mobiliza-
ion  of  tissue  ionic  charges,  which  exceed  the  physiological
apacity  of  cell  membrane  transport,  irreversibly  inter-
upting  the  cells  homeostasis.  Unlike  the  other  physical
estruction  techniques,  electroporation  is  not  therefore  a
hermotherapy  although  there  is  a  minor  Joule  effect.
The  results  of  electroporation  are  not  therefore  in
rinciple  affected  by  the  thermal  blood  ﬂow  convection
ffect.  In  addition,  as  the  Joule  effect  of  electroporation
s  negligible,  the  method  does  not  denature  macropro-
eins  such  as  collagen  ﬁbers.  Although  their  cell  component
s  ‘‘affected’’  the  ‘‘electrophoresed’’  tissues  retain  an
ntact  connective  tissue  architecture.  Small  bile  ductules
nd  vessels  within  the  electroporesed  areas  therefore  often
emain  patent.  Electroporation  is  therefore  particularly
romising  to  treat  central  hilar  liver  tumors  in  which  ther-
otherapies  are  contraindicated  because  of  the  risks  of
iliary  stenosis.  In  practical  terms,  alongside  multipolar
adiofrequency,  ablation  electroporation  also  relies  on  the
rinciple  of  implanting  several  electrodes  (2  to  6),  which
re  sequentially  activated  in  pairs  in  bipolar  mode  (Fig.  2).
lectrolocalization  is  a technique,  which  is  still  not  widely
sed:  few  clinical  results  have  been  published  and  patient
umbers  have  been  small,  with  limited  follow  up.  Neverthe-
ess,  its  speciﬁc  aspects,  which  make  the  method  a  relatively
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afe  treatment  option  in  inoperable  juxtahilar  liver  tumors
ave  been  conﬁrmed  [24].
ther technologies
ther  physical  destruction  methods  are  used  including
aser  photocoagulation,  cryotherapy  and  focused  ultra-
ound.  Although  clear  technological  improvements  have
een  made  with  these  techniques  over  recent  years,  their
se  in  treating  liver  tumors  is  still  marginal.  They  have  not
et  shown  to  offer  sufﬁcient  advantages  over  other  thermal
ethods  to  justify  their  more  widespread  use.
ndications and contraindications for
ercutaneous ablation of liver tumors
ndications
urative  treatment
longside  excision  surgery,  percutaneous  ablation  tech-
iques  form  part  of  the  radical  curative  local  treatments.
hey  are  therefore  conventionally  considered  in  patients
ho  do  not  have  widespread  disease  and  who  do  not  have
xtrahepatic  spread.  The  most  widely  accepted  rule  for  per-
utaneous  treatment  to  be  used  is  the  rule  of  ‘‘two  3s’’:  3  cm
aximum  diameter  and  up  to  3  concomitant  sites.
a
c
i
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igure 3. Eighty-one-year-old female patient with a peripheral cholan
ultipolar radiofrequency ablation. The mass on computed tomography
nd sagittal (c) sections. One month after multipolar radiofrequency ab
rtiﬁcial ascites: axial (d) coronal (e) and sagittal (f) CT showing comple
uprahepatic vessels.O.  Seror
The  debate  over  the  place  of  percutaneous  treatments
ompared  to  their  direct  competitor,  excision  surgery,  is
till  wide  open.  Radiofrequency  ablation  is  still  very  often
escribed  as  a  salvage  treatment  in  patients  not  accepted
or  excision,  although  there  are  no  robust  data  justifying  this
trategy  either  for  metastases  (of  colorectal  cancers)  [25]
r  for  HCC  [26]. For  similar  patient  groups,  survival  after
urgery  is  not  signiﬁcantly  better  than  after  radiofrequency
blation  [14,27],  although  compared  to  excision,  radiofre-
uency  treatment  is  far  better  tolerated  and  less  expensive.
t  can  also  be  easily  repeated  in  the  event  of  recurrence
which  occurs  in  over  ﬁfty  per  cent  of  patients  5  years  after
xcision  or  percutaneous  treatment,  both  for  metastases
nd  for  HCC).  As  a result,  there  is  now  a  strong  basis  for
ffering  patients  radiofrequency  ablation  ﬁrst  line  for  small
umors  (≤  3  cm  in  monopolar  mode  and  ≤  5  cm  in  multipolar
ode),  including  those  with  operable  disease.
ombined  treatments
ercutaneous  treatments  are  usually  only  considered  in
ore  extensive  disease  in  combination  with  other  treat-
ents  such  as  hepatectomy,  chemotherapy  for  metastases
6]  or  chemoembolization  for  HCC.  The  purpose  of  these
ombined  treatments  is  also  to  completely  eradicate  any
ctive  lesion  (0  residual  tumor  [R0]).  Multipolar  mode,  which
an  completely  and  reproducibly  destroy  tumors  up  to  8  cm
n  diameter  [19]  can  reduce  the  need  for  treatment  combi-
ations,  which  can  occasionally  be  poorly  tolerated  (Fig.  3).
giocarcinoma 8 cm in diameter in the dome of the liver treated by
 (CT) before treatment in the portal phase on axial (a) coronal (b)
lation (6 electrodes) and protection of the diaphragm by creating
te destruction of the tumor area up to contact with the portal and
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The  arrival  of  second-generation  microwave  devices  enable
‘‘one  shot’’  ablations  of  small  tumors  (≤  3  cm)  in  under  three
minutes  (application)  and  offers  future  prospects  for  multi-
focal  disease  (>  3  sites)  or  multiple  recurrences  (multicenter
carcinogenesis).  In  this  case,  ablation  appears  to  be  used  less
to  eradicate  the  cancer  than  to  attempt  to  achieve  long-
term  control,  preserving  patient’s  best  possible  quality  of
life.
‘Holding’  treatment  pending  liver  transplantation
for HCC
Patients  in  France  with  a  small  HCC  (Milan  criteria:  1  nod-
ule  ≤  5 cm  or  up  to  3  nodules  ≤  3  cm),  which  has  developed
in  well-compensated  cirrhosis  (Child-Pugh  A)  have  waiting
time  of  approximately  1  year  for  a  transplant.  The  ques-
tion  therefore  often  arises  as  to  the  beneﬁt  of  treating  the
HCC  pending  transplantation  in  order  to  keep  the  patient
within  the  Milan  transplantation  criteria.  Percutaneous
treatments,  chemoembolization  and  even  a  combination  of
both  techniques  are  often  used  in  this  situation.  Some  Euro-
pean  centers  have  reported  that  over  30%  of  patients  who
have  not  been  treated  come  off  the  waiting  list  because  of
tumor  progression  [28].  In  reality,  the  problem  which  arises
is  not  to  know  whether  percutaneous  treatments  can  keep
patients  within  the  eligibility  criteria  for  transplantation
(the  answer  to  this  is  obviously  yes)  but  to  ensure  that  the
post-transplant  prognosis  of  patients  who  have  had  ‘hold-
ing’  treatment  pending  transplantation  is  similar  to  that  in
patients  who  have  been  transplanted  as  early  as  possible.
There  is,  however,  no  tangible  evidence  in  the  literature  to
answer  this  question,  although  it  is  a  crucial  one.  The  risk
of  tissue  dissemination  along  the  needle  puncture  path  is
often  cited  as  a  reason  to  opt  for  chemoembolization  pend-
ing  transplantation.  This  solution  does  not  appear  to  be  well
founded  as  chemoembolization  only  achieves  total  necro-
sis  of  small  HCC  in  under  a  third  of  cases  [29]. Because
of  the  shortage  of  transplants,  access  to  transplantation
is  being  increasingly  limited  for  patients  with  HCC  who  do
not  have  liver  impairment.  In  reality,  the  majority  of  these
‘‘technically  transplantable’’  patients  will  never  be  trans-
planted.  ‘‘Holding’’  treatment  is  therefore  more  likely  to
be  the  only  ﬁrst  line  tumor  therapy,  which  they  will  receive
i
c
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Figure 4. Sixty-year-old male patient with superﬁcial hepatocellular 
quency ablation. Computed tomography (CT) in the arterial phase (a) s
in diameter. One month after no touch multipolar radiofrequency abla
excellent safety margins. 669
or  several  months.  This  treatment  should  therefore  be  as
adical  as  possible  in  order  to  offer  the  patient  the  best
hances  of  long-term  survival.  Using  the  Milan  criteria  and
part  from  excision,  only  percutaneous  destruction  tech-
iques  are  potentially  curative  and  they  should  therefore  be
sed  in  priority,  including  situations  when  transplantation
s  planned,  because,  as  described  above,  transplantation
s  far  from  a  certainty  in  patients  with  good  liver  func-
ion.  In  addition,  a  ‘‘salvage’’  transplant  is  still  possible
n  these  patients  if  their  HCC  recurs  after  percutaneous
reatment  [19].  The  risk  of  dissemination  should  not  there-
ore  be  overstated  and  should  always  be  assessed  depending
n  the  speciﬁc  clinical  situation.  Risks  of  dissemination  are
ncreased  in:
subcapsular  tumors  which  cannot  be  approached  with-
out  passing  through  non-malignant  liver  tissue  (less  than
1  cm);
when  initial  (unprotected)  biopsies  have  been  taken;
greatly  elevated  serum  -fetoprotein  concentrations;
poorly  differentiated  tumors  (>  Edmonson  grade  II).
In  these  situations,  ‘‘no  touch’’  multipolar  mode  is  a  very
ttractive  alternative  [19]  (Figs.  2  and  4).
alliative  treatment
artial  resection  of  malignant  liver  tumors  does  not  signiﬁ-
antly  prolong  patient  survival  and  surgical  tumor  reduction
s  therefore  not  indicated.  In  addition,  hepatectomy  can
nly  be  considered  in  patients  with  liver  metastases  if  the
rocedure  would  remove  all  visible  tumors  (R0).  This  sur-
ical  concept  has  been  extrapolated  to  the  percutaneous
reatments  which  are  not  conventionally  therefore  indi-
ated  for  palliative  use.  One  randomized  trial,  however,  has
hown  that  the  combination  of  radiofrequency  ablation  with
hemotherapy  signiﬁcantly  prolongs  survival  in  patients  with
etastatic  liver  disease  (colorectal  in  origin)  in  whom  R0
xcision  cannot  be  achieved  [30].  No  comparable  data  are
urrently  available  for  HCC.  It  is  possible,  however,  that  as
n  the  example  of  the  palliative  treatment  par  excellence,
hemoembolization,  a  reduction  in  tumor  volume  with  per-
utaneous  treatment  could  lead  to  improved  survival  in
ome  patients.
carcinoma in segment III treated by no touch multipolar radiofre-
hows a subcapsular, hepatocellular carcinoma in segment III, 3 cm
tion the CT (b) shows appearances of complete destruction with
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ontraindications
emostasis
here  are  few  absolute  contraindications  and  these  are
ostly  concern  patients  at  high  risk  of  bleeding.  Conven-
ionally,  patients  with  serious  coagulation  abnormalities  are
herefore  excluded.  The  contraindications  to  percutaneous
reatments  for  most  groups  are:
prothrombin  ratio  <  50%;
platelet  count  <  50,000;
activated  partial  thromboplastin  time  >  10  points  over  the
control.
Although  not  formally  proven,  thermoregulation  of  the
eedle  puncture  path  at  the  end  of  the  procedure  by  slowly
ithdrawing  activated  electrodes  ‘‘hot  withdrawal’’  (which
s  impossible  with  electroporation  and  difﬁcult  or  even  dan-
erous  with  microwave)  is  recommended  in  order  to  reduce
he  risk  of  bleeding.  This  maneuver  also  reduces  the  risk  of
umor  dissemination.
irrhosis
aradoxically,  cirrhosis  does  not  appear  to  either  increase
r  worsen  bleeds  after  percutaneous  ablation.  The  risks  of
iver  decompensation,  however,  are  greater  in  patients  who
ave  the  most  severe  coagulation  abnormalities.
Clinical  ascites  is  also  one  of  the  contraindications  for
adiofrequency  ablation,  as  the  risk  of  bleeding  appears  to
e  greater.  Major  ascites  on  a  background  of  cirrhosis  is  an
ndication  of  serious  liver  dysfunction,  a  situation,  which
enerally  contraindicates  any  treatment  for  HCC.
ite
ome  anterior  subcapsular  tumors  cannot  be  punctured
irectly  without  passing  through  non-malignant  liver  tissue.
he  risk  of  bleeding  complications  and  tumor  dissemination
s  greater  in  this  situation.  Limited  resection  is  often  the  best
lternative  treatment  for  these  tumors  and  is  a  particularly
easonable  option  as  the  procedure  is  technically  straight-
orward  and  limited.  As  we  have  described,  if  surgery
s  contraindicated,  ‘‘no  touch’’  multipolar  radiofrequency
O
t
r
o
igure 5. Sixty-ﬁve-year-old female patient with left intraportal hepa
raphy in the arterial phase (a) shows a left intraportal hypervascular ma
ynamic MRI in the arterial phase (b) shows appearances of complete deO.  Seror
blation  is  an  attractive  alternative  to  percutaneous  meth-
ds  (Fig.  4).
Other  tumor  site  contraindications  are  often  quoted
epending  on  the  center,  equipment,  technique  and  experi-
nce  of  the  operators.  Some  tumor  sites  carry  large  risks
f  collateral  damage.  This  applies  particularly  to  central
hilar)  tumors,  which  carry  a  risk  of  biliary  stenosis.  Treat-
ent  of  tumors  located  close  to  the  gastrointestinal  tract,
articularly  the  colon,  are  at  greater  risk  of  peritonitis  from
erforation  and  the  minimum  safe  distance  of  1  centimeter
etween  the  border  of  the  tumors  and  these  structures  is
ommonly  recommended.  Some  preventative  measures  such
s  cooling  the  biliary  tract  by  endoluminal  injection  of  iced
ater  when  the  energy  is  delivered  or  retracting  the  treat-
ent  area  from  gastrointestinal  structures  by  hydro-  or  gas
issection,  allow  these  sites  to  be  treated  in  some  situations
hen  no  surgical  alternative  is  available  [3].
Percutaneous  treatment  of  other  sites  such  as  tumors
ocated  close  to  the  gallbladder  or  diaphragm  also  requires
ome  precautions,  particularly  when  the  contact  areas
xtend  over  a centimeter.  In  order  to  protect  the  diaphragm
rtiﬁcial  ascites  is  created  with  dextrose  before  the  proce-
ure  (ﬁlling  the  peritoneal  cavity  by  injecting  1  to  3  L  of  5%
lucose  with  the  patient  in  the  Trendelenburg  position).  The
allbladder  can  be  drained  preventatively  or  even  cooled  by
irculating  water  (in  this  case  the  cooling  circuit  requires
ual  catheterization  of  the  gallbladder).  In  addition,  elec-
roporation,  which  is  not  a  thermotherapy,  could  be  a  ﬁrst
ine  technique  in  these  situations,  if  its  preliminary  results
re  conﬁrmed  (Fig.  5).
on-functional  sphincter  of  Oddi
atients  with  a  previous  history  of  biliary-gastrointestinal
nastamosis  or  sphincteroctomy  have  a  50%  risk  of  develop-
ng  an  abscess  in  the  thermal  ablation  area.  No  antibiotic
rophylaxis  or  antibiotic  therapy  has  been  shown  to  be
ffective  in  preventing  this  complication.  It  is  difﬁcult,  how-
ver,  to  consider  patients  without  a  functional  sphincter  of
ddi  but  who  are  also  inoperable  and  have  an  absolute  con-
raindication  for  any  percutaneous  treatment,  as  this  would
emove  the  last  possibility  of  curative  treatment.  The  risk
f  percutaneous  treatment  may  be  taken  in  this  situation
tocellular carcinoma treated by electroporation. Computed tomo-
ss. One month after irreversible electroporation (with 4 electrodes)
struction with no related biliary damage.
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provided  that  the  patients  are  monitored  very  carefully  in
the  weeks  after  the  procedure.  Any  abscess,  which  develops
should  be  treated  promptly  with  drainage  and  appropriate
antibiotic  therapy.
Electromagnetic  interferences
Delivering  electromagnetic  pulses  close  to  a  pacemaker
can  theoretically  damage  it.  In  practice,  this  applies  with
monopolar  RF  and  microwaves  but  not  with  bipolar  RF  (as
in  order  for  interference  to  develop,  the  pacemaker  would
need  to  be  located  between  the  two  active  electrodes!).
From  this  perspective,  multipolar  RF  is  the  safest  tech-
nique.  In  reality,  monopolar  and  microwave  ablation  may
be  carried  out  in  patients  with  pacemakers  [31]  although  a
cardiology  opinion  is  recommended  before  the  procedure.  If
the  decision  is  made  to  continue,  these  patients  should  be
treated  under  ad  hoc  resuscitation  safety  conditions.  Elec-
troporation  which  also  uses  bipolar  mode  but  with  very  high
RF  intensities  and  potentials  is,  however,  completely  con-
traindicated  in  heart  disease  (of  any  type)  because  of  the
risk  of  a  serious  arrhythmia  (even  if  the  RF  pulses  are  only
delivered  during  the  ECG  refractory  period  [S-T]).
Conclusion
The  emergence  of  effective  reproducible  mini-invasive  per-
cutaneous  treatments  such  as  radiofrequency  has  profoundly
changed  the  management  of  small  malignant  liver  tumors
for  which  the  only  radical  treatment  until  recently  has  been
excision  surgery.  Outside  of  the  transplantation  situation,
the  ﬁrst  line  treatment  of  early  stages  (TNM  I)  of  HCC
should  now  be  with  percutaneous  ablation  techniques.  There
is  a  well-acknowledged  lack  of  information  in  the  litera-
ture  to  establish  the  exact  role  of  percutaneous  methods
for  treatment  of  localized  hepatic  metastases,  particularly
those  from  colorectal  cancer  compared  to  excision  surgery.
It  does,  however  appear  here  again  that  percutaneous  meth-
ods  can  offer  long-term  survival,  which  is  entirely  similar
to  the  survival  obtained  after  hepatectomy.  These  still  too
scarce  ﬁndings  should  be  followed  by  randomized  trials
to  compare  percutaneous  techniques  with  excision  for  the
treatment  of  metastases.
Combination  treatments  using  percutaneous  destruction
techniques  and  endarterial  therapies  have  long  been  con-
sidered  to  be  the  most  promising  strategies  to  improve  and
extend  the  indications  for  the  percutaneous  treatments.
Considerable  technological  advances  in  recent  years  have
brought  new  future  prospects  for  treatment.  The  second-
generation  microwave  devices,  which  are  far  faster  than
monopolar  radiofrequency  ablation  technically,  enable  com-
plete  treatment  of  5  to  8  small  (≤  3  cm)  liver  tumors  in
a  single  session.  Multipolar  radiofrequency  ablation  can
achieve  controlled  thermo-ablation  of  both  small  and  larger
tumors  (>  5  cm,  <  8  cm),  whether  or  not  these  are  superﬁcial.
Irreversible  electroporation  now  offers  radical  treatment
for  central,  inoperable  liver  tumors.  These  new  treatment
methods  clearly  need  to  be  conﬁrmed  on  a  larger  scale
although  the  speed  of  technological  change  in  the  ﬁeld  of
ablation  is  such  that  now  even  more  than  before  our  clinical 671
esearch  must  be  permanently  incorporated  into  our  routine
linical  practice.
linical case
 57-year-old  man  followed  up  for  Child-Pugh  A  5  mixed
ost-HVC  and  alcoholic  cirrhosis  (the  patient  was  still  drink-
ng)  (PR  60%,  Bilirubin  30  g/mL)  was  found  to  have  four
odules  under  3 cm  in  diameter  with  (CT)  appearances
f  hepatocellular  carcinoma.  His  alpha-fetoprotein  was
0  ng/mL  (Fig.  6).
uestions
.  What  treatment  would  you  consider?
A.  Transplantation.
B.  Excision.
C.  Chemoembolization.
D.  Ablation(s).
.  Which  of  the  ablation  techniques  do  you  think  is  most
appropriate?
A.  Multipolar  radiofrequency  ablation.
B.  Electroporation.
C.  Microwave.
D.  Conventional  monopolar  radiofrequency  ablation.
.  The  lesions  are  not  entirely  visible  on  ultrasound:
A.  This  is  a  contraindication  to  ablation  techniques:
arterial  chemoembolization  therapy  would  be  better.
B.  The  ablation  procedure  should  be  performed  under
CT  guidance.
C.  The  ablation  procedure  should  be  performed  by  ﬂat
sensor  angiography  with  cone  beam  CT  guidance.
D.  Ultrasound  guidance  with  pre-treatment  CT  or  MR
guidance  could  be  considered.
.  The  repeat  CT  performed  a  month  after  treatment  shows
a  good  response  in  the  four  lesions  treated.  Three  months
later,  however,  when  the  patent  had  stopped  drinking
completely  and  his  liver  function  had  improved,  three
new  nodules  were  found.  What  do  you  propose?  (Fig.  7):
A.  Chemoembolization.
B.  Radioembolization.
C.  Transplantation.
D.  A  percutaneous  ablation  procedure.
nswers
.  Answer  D.  A.  Temporary  contraindication  to  HT  (the
patient  has  not  stopped  drinking).  If  the  patient
stopped  his  excessive  alcohol  consumption  the  aver-
age  transplant  waiting  time  is  1  year  for  Child-Pugh
A  disease.  He  is  slightly  outside  of  the  Milan  crite-
ria  (tumors  <  3  cm  although  number  >  3).  As  a minimum,
therefore,  ‘‘holding’’  treatment  should  be  offered.  B:
more  than  three  segments  contain  tumor  and  active  cir-
rhosis  is  present.  These  represent  a  contraindication  to
excision  surgery.  C.  This  is  the  treatment  very  often
recommended  in  this  situation  of  multifocal  HCC.  It  is
therefore  by  necessity  non-selective.  The  risk  of  deterio-
ration  of  liver  function  after  treatment  is  high  in  this  case
in  an  alcoholic  patient  who  is  still  drinking.  In  addition,
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Figure 6. Three computed tomography section levels in the arterial phase of contrast enhancement showing four hypervascular nodules
( 3 cm 
o ng).
2
3
4with wash-out in the portal phase not shown on the ﬁgure) under 
f ascites indicating decompensated cirrhosis (alcoholic, still drinki
the  effect  of  endarterial  therapy  is  difﬁcult  to  predict
and  rarely  complete  (it  is  a  palliative  treatment).
.  Answer  C  and  D  (Fig.  8).  A.  The  challenge  in  this  situation
is  to  control  the  disease  as  radically  as  possible  without
deteriorating  liver  function.  Multipolar  RF  achieves  near
constant  average  safety  margins  of  1  cm  when  the  nod-
ules  are  small,  as  they  are  in  this  case  (<  3  cm).  With  4
tumors,  however,  a  signiﬁcant  amount  of  functional  liver
parenchyma  would  be  sacriﬁced.  The  beneﬁt/risk  bal-
ance  of  multipolar  RF  does  not  therefore  appear  to  be
positive  in  this  case.  B.  This  is  a  new  technique,  which
has  not  been  shown  to  be  effective  compared  to  the  more
conventional  methods  such  as  RF  or  microwave.  Elec-
troporation  is  a  reasonable  method  if  thermotherapies
(RF  MW)  are  absolutely  contraindicated,  particularly  for
central,  inoperable  tumors  juxtapositioned  between  the
vascular  convergence  and  common  bile  duct.
.  Answer  D.  A.  Fusion  and  virtual  navigation  technologies
have  greatly  improved  guiding  imaging  in  recent  years.
Lesions,  which  cannot  be  seen  on  ultrasound  can  now
be  located  and  treated  in  most  cases  using  these  tech-
nologies.  B.  This  is  far  more  intensive,  time  consuming
(human  and  machine),  exposes  the  patient  to  irradia-
tion  (multiple  nodules)  and  also  inexact  (poor  contrast
in  the  liver  nodules  without  enhancement).  C.  Compared
to  CT  these  new  generation  angiography  tables  are  help-
ful  as  they  allow  better  patient  accessibility.  They  also
have  rotational  3D  (cone  beam  CT)  guiding  and  fusionin diameter. Note also the hepatic dysmorphism and small amount
instruments,  which  allow  the  difﬁcultly  located  target  to
be  punctured.  These  low  contrast  images  do  in  addition,
however,  deliver  a  relatively  large  amount  of  irradiation
(high  angular  sampling  of  the  RX  beams  for  images  with
the  best  tissue  contrast).
.  Answer  C  and  D.  A.  This  is  an  option,  but  why  choose
a  treatment  which  is  only  partially  effective  and  unpre-
dictable  when  there  are  ‘‘only  three’’  small  lesions?  B.
This  is  a  treatment  currently  being  assessed,  which  has
not  been  shown  to  be  superior  to  chemoembolization.  C.
Yes,  in  this  young  patient  who  has  stopped  excessive  alco-
hol  consumption.  Transplant  would  seem  at  present  the
best  long-term  treatment  option.  Local  or  locoregional
treatments,  even  if  effective,  will  not  prevent  the  later
development  of  new  lesions  as  this  patient  has  evidence
of  multicenter  carcinogenesis.  He  is  still  however  Child-
Pugh  stage  A  and  his  liver  function  has  even  improved,
so  a  transplant  waiting  time  of  at  least  a  year  should  be
planned.  D.  Percutaneous  ablation  is  a  perfectly  appro-
priate  ‘‘holding’’  treatment  pending  transplantation.  It
also  has  the  advantage  over  chemoembolization  of  being
repeatable  almost  without  limit  (as  long  as  there  are
not  too  many  lesions)  and  being  more  radical.  This  is
signiﬁcant,  as  transplantation  remains  a  possibility  for
all  patients  on  the  list.  There  is  of  course  a  risk  of
dissemination  along  the  puncture  path  after  percuta-
neous  treatment.  This  risk  is  sufﬁciently  low,  however,
not  to  represent  an  absolute  contraindication  in  patients
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Figure 7. Three computed tomography section levels in the arterial phase of contrast enhancement showing areas of destruction by
application of microwave energy.
Figure 8. Strategy plan for multiple percutaneous ablations to reduce the number of punctures and length of the procedure.
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awaiting  transplant.  The  risk  is  particularly  low  in  our
patient  as  none  of  the  lesions  to  be  treated  are  located
beneath  the  capsule.
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